University of North Florida

UNF Digital Commons
UNF Graduate Theses and Dissertations

Student Scholarship

2014

Meta-Analysis of Herbal Cannabis Therapy for Chronic Pain
Michael J. Seneca
University of North Florida, n00152876@ospreys.unf.edu

Follow this and additional works at: https://digitalcommons.unf.edu/etd
Part of the Medical Pharmacology Commons, Medicinal and Pharmaceutical Chemistry Commons,
Natural Products Chemistry and Pharmacognosy Commons, Nursing Commons, and the Pharmacy
Administration, Policy and Regulation Commons

Suggested Citation
Seneca, Michael J., "Meta-Analysis of Herbal Cannabis Therapy for Chronic Pain" (2014). UNF Graduate
Theses and Dissertations. 503.
https://digitalcommons.unf.edu/etd/503

This Doctoral Project is brought to you for free and open
access by the Student Scholarship at UNF Digital
Commons. It has been accepted for inclusion in UNF
Graduate Theses and Dissertations by an authorized
administrator of UNF Digital Commons. For more
information, please contact Digital Projects.
© 2014 All Rights Reserved

META-ANALYSIS OF HERBAL CANNABIS THERAPY FOR CHRONIC PAIN
by
Michael J. Seneca

A project submitted to the School of Nursing
in partial fulfillment of the requirements for the degree of
Doctor of Nursing Practice
UNIVERSITY OF NORTH FLORIDA
BROOKS COLLEGE OF HEALTH
March 2014
Unpublished work c. Michael J. Seneca

Certificate of Approval

The project of Michael J. Seneca is approved:

Dan Richard, PhD
Committee Member

Jonathan Pabalate, DNP, CRNA
Committee Member

Carol Ledbetter, PhD, FNP, BC, FAAN
Committee Member

Doreen Radjenovic, PhD, ARNP, BC
Committee Chairperson

7-12-2013
Date

7-12-2013
Date

7-12-2013
Date

7-12-2013
Date

Accepted for the School of Nursing:

Lillia Loriz, PhD, GNP, BC
Director, School of Nursing

Date

Accepted for the College:

Pamela S. Chally, PhD, RN
Dean, Brooks College of Health

Date

Accepted for the University

Len Roberson, PhD
Dean of the Graduate School

Date

iii
Dedication & Acknowledgements
I would like to thank Dr. Doreen Radjenovic for providing guidance throughout the completion
of this project. I would also like to thank Dr. Carol Ledbetter for her support and guidance on the
project. I also wish to thank Drs. Richard and Pabalate for their input and contributions as
committee members. Finally, I’d like to thank my wife, Martha, for her patience and fortitude as
we completed this journey together.

iv
Table of Contents

List of Tables ..................................................................................................................... vi
List of Figures .................................................................................................................. vii
Abstract ........................................................................................................................... viii
Chapter One: Introduction ..................................................................................................1
Background ..................................................................................................................1
Policy Influences..........................................................................................................1
Abbreviated Literature Review....................................................................................3
Problem ........................................................................................................................6
Project Purpose ............................................................................................................7
Definition of Terms......................................................................................................7
Chapter Two: Review of Literature ....................................................................................9
Systematic Reviews of Cannabinoids..........................................................................9
Systematic Reviews of Herbal Cannabis ...................................................................10
Review of CMCR-Funded Research .........................................................................12
Summary....................................................................................................................13
Chapter Three: Methodology ............................................................................................15
Search Strategy ..........................................................................................................15
Study Selection ..........................................................................................................16
Outcome Measures.....................................................................................................17
Statistical Analysis.....................................................................................................18
Chapter Four: Results ........................................................................................................20
Meta-Analysis Results ...............................................................................................20
Chapter Five: Discussion ...................................................................................................23
Implications for Practice ............................................................................................23
Study Limitations.......................................................................................................25
Implications for Research ..........................................................................................26
Conclusion .................................................................................................................27

v
Appendix
Experimental Studies Investigating Herbal Cannabis and Chronic Pain...................29
References .........................................................................................................................31

vi
List of Tables
Table 1: States That Have Enacted Medical Marijuana Legislation .................................14
Table 2: Meta-Analysis of Herbal Cannabis in Reduction of Pain Intensity.....................21

vii
List of Figures
Figure 1: Funnel plot to assess publication bias ................................................................22

viii
Abstract
Since the first so-called “medical marijuana” legislation was passed in California in 1996, a total
of twenty states and the District of Columbia have passed laws permitting limited use of
cannabis. Despite the changes in state laws, cannabis remains illegal for any purpose under
federal law. Changes in state laws have coincided with a renewed interest in the substance for the
treatment of a variety of conditions. There has been a significant increase in published data over
the past twenty years examining the efficacy of cannabis as an appetite stimulant, antiemetic
agent, and analgesic adjuvant. The purpose of this meta-analysis was to synthesize published
data on cannabis use as an analgesic agent. Five studies meeting inclusion criteria were located
through searches of online databases, review of reference lists, author correspondence, and
review of clinical trials databases. Meta-analysis was conducted using fixed-effects modeling.
The overall effect of mean reduction of pain intensity was -4.895 (Z-score) with an associated p
value of 0.003. The combined standardized mean difference (SMD) was -0.362 (CI -0.507 to 0.217), indicating on average a moderate significant reduction in pain intensity for patients with
chronic pain. As the legal status of the substance evolves, additional research is needed to
establish evidence-based clinical recommendations regarding the use of medicinal cannabis in
pain management.

Keywords: cannabis, marijuana, chronic pain, neuropathic pain
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Chapter One: Introduction
Background
In the past decade, there has been a renewed interest in the use of cannabis for therapeutic
purposes to treat a variety of ailments and conditions. Despite federal prohibition of the
substance, so called “medical marijuana” laws have been enacted in the United States in twenty
states and the District of Columbia over the last 16 years (Procon, 2013). The literature is replete
with studies regarding clinically available synthetic cannabinoid agents. Given the legal
ramifications, however, data regarding the clinical use of herbal cannabis is much more limited.
The purpose of this project is to review the available literature and, using meta-analytic
methodology, evaluate what is currently known regarding the effects of cannabis in the treatment
of chronic pain.
Policy Influences
At the present time, the Drug Enforcement Administration (DEA) classifies cannabis as a
“Schedule I” substance. According to the Comprehensive Drug Abuse Prevention and Control
Act of 1970, categorization as a Schedule I substance means that the substance has been deemed
to have no accepted medical use, a high potential for abuse, and a lack of any accepted margin of
safety for usage. The placement of cannabis within this schedule remains controversial. All three
of these requirements have been challenged through several formal petitions to the DEA over the
past three decades (Gettman, 2004; Americans for Safe Access v. DEA, 2012). A total of twenty
states and the District of Columbia have enacted legislation allowing for medical use of cannabis
under a variety of conditions (Table 1). While this new legislation permits usage under state
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laws, cannabis remains illegal for any purpose under federal law, except under very limited
conditions for research purposes (Table 1).
Since the first medical marijuana legislation was enacted in California in 1996, there has
been a significant increase in published data regarding the medical use of cannabis in the
treatment of a variety of conditions. There is a considerable amount of published literature
related to the ability of medicinal cannabis to promote appetite and minimize weight loss in
chronic and terminal disease states such as AIDS and cancer (Machado Rocha, Stéfano, De
Cassia Haiek, Rosa Oliveira, & Da Silveira, 2008; Tramér et al., 2001). The FDA-approved
cannabinoid agonist dronabinol (Marinol) is labeled for use to promote appetite in chronic
disease states and treat nausea and vomiting associated with chemotherapy (“New Drug
Approvals,” 1985).
While evidence of the analgesic properties of cannabis was published in the 19th century
(O’Shaughnessy, 1843), the use of cannabis for this purpose diminished significantly into the
early 20th century. The recognition of the analgesic potential of cannabis in Europe and the
United States emerged around the same time as the invention of the hypodermic needle in 1857.
During the middle and late 19th century, a variety of cannabis preparations were marketed in
Europe and the United States for the treatment of discomfort related to numerous common
ailments. At the turn of the 20th century, cannabis continued to be recommended by mainstream
physicians and maintained a place on pharmacopeias in both the United States and Britain
(Russo, 1998). Dr. William Osler, one of the founders of Johns Hopkins Hospital recommended
cannabis for the treatment of migraine headaches as late as 1915 (Osler & McCrae, 1915).
However, a number of factors contributed to a decreased prevalence of these preparations going
further into the 20th century, including an association of the use of cannabis with certain classes
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of people, vaccines for diseases that cannabis previously served to treat symptoms of, effective
treatments for a number of diseases, the discovery of aspirin, increased opioid usage, and a
preference for parenteral administration of medications (Grinspoon & Bakalar, 1993).
More recent research that has emerged in the last two decades has confirmed historical
data and anecdotal evidence that cannabis is useful as an appetite stimulant, antiemetic agent,
and analgesic adjuvant. In 1999, the United States Institute of Medicine (IOM) published an
extensive report on the topic of medical marijuana, concluding that cannabinoids most likely
play a role in pain modulation. Further, the 1999 IOM report suggested that cannabis has an
acceptable margin of safety and recommended further research on the medicinal use of cannabis
for a variety of conditions, including chronic pain states.
Abbreviated Literature Review
Mechanism of Action
It has long been recognized that cannabis possesses analgesic properties (O’Shaughnessy,
1843; Dixon, 1899). Recent studies have suggested that cannabis promotes analgesia through
supraspinal modulation of nociception via the periaqueductal grey (PAG)-rostral ventromedial
medulla (RVM)-dorsal horn (DH) axis (Palazzo, Luongo, Novellis, Rossi, & Maione, 2010). In
addition to the role in central modulation of pain, there is also data to support a peripheral action
of cannabis via peripheral cannabinoid type 1 (CB1) receptors (Richardson, Kilo, & Hargreaves,
1998).
Conflicting Findings With Hyperalgesia
The antinociceptive and antihyperalgesic properties of cannabis present in a delayed
biphasic manner with a window of analgesia at lower doses and increased nociception at high
doses (Wallace et al., 2007). The biphasic nature of the analgesic dose-response complicates
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assessment of the analgesic properties of cannabis. A study by Kraft et al. (2008) actually
demonstrated the development of a hyperalgesic state as a result of oral cannabis extract.
Participants in the Kraft et al. study received controlled localized ultraviolet burns to their lower
extremities to provide a model for evaluating heightened sensitivity to pain. Kraft et al. found
that participants who received higher doses of oral cannabis extracts demonstrated heightened
sensitivity to pain, or hyperalgesia, over a larger area. Comparison of the Kraft et al. findings
with the findings by Wallace et al. is problematic for several reasons. Participants in the Kraft et
al. study received capsules of cannabis extract rather than inhaled herbal cannabis, allowing for
the possibility that first-pass metabolism and pharmacokinetic variability may have contributed
to the different findings. When tetrahydrocannabinol (THC) is administered orally, only 10-20%
of the compound reaches the systemic circulation unchanged (Agurell et al., 1986). An additional
issue is that plasma levels of active compounds were not monitored in the Kraft et al. (2008)
study, making direct comparison with the dosing in the Wallace et al. (2007) study problematic.
Finally, cannabis extracts commonly contain one or two active compounds, such as
tetrahydrocannabinol or cannabidiol. Herbal cannabis smoke is known to contain more than 525
components, at least 80 of which have been shown to be biologically active (Radwan et al.,
2009; ElSohly & Slade, 2005). Generalizability of findings utilizing oral cannabis preparations
that contain one or two active compounds with inhaled herbal cannabis is limited.
Experimental Trials Using Cannabis
Human research on the clinical benefits of cannabis has been limited by legal restrictions,
but available data indicates a potentially beneficial effect of cannabis for a variety of pain states.
Treatment of neuropathic pain in multiple sclerosis has been improved by the use of cannabis in
clinical trials (Hosking & Zajicek, 2008). In a randomized controlled trial by Ware et al. (2010),
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patients suffering from chronic neuropathic pain who smoked cannabis cigarettes experienced
reduced pain intensity and improved sleep without significant side effects. The analgesic effects
observed in the study by Ware et al. were absent in the control group, who received cannabis
with a reduced quantity of active compounds. Research published previously indicated similar
analgesic benefits to patients suffering from neuropathic pain. A randomized controlled trial
conducted by Ellis et al. (2009) found that patients who received cannabis containing 8% THC
experienced a significant reduction in HIV-associated neuropathic pain when compared with the
placebo group (who received cannabis with THC removed). The 2009 Ellis et al. study replicated
findings from an earlier study by Abrams et al. (2007a) that found a similar reduction in HIVassociated neuropathic pain in participants who received cannabis with THC present when
compared with participants who received cannabis with THC removed.
Recent research has also demonstrated opioid-sparing properties of cannabis when it is
used as an adjunct agent in pain management. Cannabis contributes to cumulative analgesia,
reduces opioid consumption, and prevents or diminishes development of tolerance to and
withdrawal from opioids (Lucas, 2012). An inpatient open trial conducted by Abrams, Couey,
Shade, Kelly and Benowitz (2011) demonstrated that vaporized cannabis reduced pain by an
average of 27% in chronic pain patients receiving twice-daily dosing of sustained-release
morphine or oxycodone without altering plasma levels of opioids. Research findings of improved
analgesia and reduced opioid consumption strongly suggest a beneficial role for cannabis as a
potential adjunct agent in some patients experiencing chronic pain. A study by Wilsey et al.
(2008) further supported the role of active cannabinoids in the analgesic benefits of cannabis
with findings that both “high-dose” (7% THC) and “low-dose” (3.5% THC) produced significant
reductions in neuropathic pain when compared with placebo.
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Problem
Meta-analysis has been conducted on the much larger body of research investigating
commercially produced THC pharmaceutical agents. A 2009 systematic review and metaanalysis conducted by Martín-Sánchez, Furukawa, Taylor, and Martin demonstrated a moderate
analgesic effect of cannabinoid preparations that may be partially or completely offset by
negative side effects. The review by Martín-Sánchez et al. evaluated eighteen clinical trials from
1975-2008. All of the studies included in the Martín-Sánchez et al. meta-analysis utilized THC
preparations as the treatment intervention rather than herbal cannabis. Prior literature reviews
such as the 2002 review by Bagshaw and the 2001 review by Campbell et al. described similar
findings of modest analgesic effects mitigated by significant side effects. Both of these older
reviews also suffer the same limitation of focusing solely on THC preparations rather than herbal
cannabis preparations that contain a variety of active compounds. To date, no meta-analysis has
been published regarding clinical trials of herbal cannabis.
As discussed in the abbreviated review of literature, several randomized controlled trials
have been published recently that evaluated the effect of herbal cannabis as an analgesic adjunct
agent in the treatment of neuropathic pain. Several of the cited studies were conducted at the
University of California Center for Medicinal Cannabis Research (CMCR) with support from the
Department of Health and Human Services (HHS), the National Institute on Drug Abuse
(NIDA), and the Food and Drug Administration (Grant, Atkinson, Gouaux, & Wilsey, 2012).
This series of studies is frequently cited in editorials related to the topic of medicinal marijuana.
However, each of the published studies evaluating herbal cannabis as an adjunct analgesic agent
has relatively small numbers of participants (n = 15-50). Compiling quantitative findings from
these studies may demonstrate a greater effect size and provide better-powered data on the topic.
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Project Purpose
The question to be addressed in this meta-analysis is whether the use of herbal cannabis
by patients suffering from chronic pain provides a reduction in pain without an unfavorable side
effect profile, as compared with currently available, FDA-approved medications and treatments.
Inclusion criteria for studies to be reviewed and analyzed are randomized controlled trials of
herbal cannabis in the treatment of chronic pain, limited to the English language. No date
limitations were set for included studies, and any non-randomized trials were excluded. The
participant population of included studies consisted of patients suffering from chronic pain,
including pain resulting from comorbidities such as cancer, AIDS, and multiple sclerosis. Study
interventions under evaluation included the usage of herbal cannabis, inhaled either through
smoking or vaporization. Herbal cannabis will be compared against conventional therapies as
well as against herbal cannabis that has been altered for reduced quantities of active compounds.
Outcomes under evaluation include quantitative pain assessment utilizing visual analogue scales
and 11-point numeric pain ratings.
Definition of Terms
Active Compound
The term active compound refers to all pharmacologically active substances found in
cannabis, including all cannabinoids.
Cannabis
The term cannabis is used interchangeably with the term marijuana, and both terms refer
to the plants Cannabis Sativa and Cannabis Indica.
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Cannabinoid
The term cannabinoid refers to chemical compounds that interact with endogenous
cannabinoid receptors, including tetrahydrocannabinol (THC).
Chronic Pain
Chronic pain is pain that is experienced, regardless of cause, for a duration of greater than
three months.
Herbal Cannabis
The term refers to the dried flowers and top leaves from the plants Cannabis Sativa and
Cannabis Indica.
Marijuana
The term marijuana is used interchangeably with the term cannabis, and both terms refer
to the plants Cannabis Sativa and Cannabis Indica.
Neuropathic Pain
Neuropathic pain refers to pain resulting from damage to nerves. Common examples of
neuropathic pain include diabetic neuropathy, postherpetic neuralgia, HIV-associated
neuropathy, alcoholic neuropathy, diabetic neuropathy, and chemotherapy-related neuropathy.
Synthetic Cannabinoid
Any artificially synthesized compound or extract that interacts with endogenous
cannabinoid receptor.

9
Chapter Two: Review of Literature
This chapter will review literature relevant to use of herbal cannabis in pain management.
A literature search of Medline utilizing the keywords “cannabis” and “pain” in addition to the
title phrases “systematic review” or “comprehensive review” returned nine results, of which four
articles were relevant. An additional article was retrieved after a manual search of the list of
publications from the Center for Medicinal Cannabis Research (CMCR) website. Additional
searches utilizing the University of North Florida library “Onesearch” tool, as well as searches
utilizing Pubmed and CINAHL did not return any additional unique relevant results. Five
systematic reviews published between 2001 and 2012 were retrieved that were relevant to
cannabis and pain management.
Systematic Reviews of Cannabinoids
The earliest systematic review relevant to the topic of cannabis and pain management
was published in BMJ in 2001. By necessity, the 2001 review by Campbell et al. focused solely
on oral cannabinoids, as no randomized controlled trials (RCTs) evaluating the effects of inhaled
herbal cannabis as an analgesic had been published prior to this review. Campbell et al.
performed a qualitative systematic review that included nine trials of oral cannabinoids with a
total of 222 patients. The findings of this first review were that oral cannabinoids were only as
effective as a single 60-milligram dose of codeine and were not beneficial in treating spasticity
or neuropathic pain (Campbell et al.). In addition to poor analgesic efficacy, oral cannabinoids
were found to often have undesirable psychotropic effects that worsened with increased dosages
while not improving analgesic efficacy (Campbell et al.).
Bagshaw published a comprehensive literature review regarding the therapeutic effects of
cannabinoids and herbal cannabis the following year in 2002 in the Journal of Palliative Care.
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The Bagshaw review was very broad in scope and evaluated the effects of cannabinoids and
herbal cannabis in the treatment of nausea and vomiting, anorexia-cachexia syndrome, spasticity,
seizures and epilepsy, hiccups, and migraines in addition to their use as an analgesic. Similar to
the prior review by Campbell et al., the Bagshaw review referenced studies that only used oral
cannabinoids when evaluating analgesic efficacy. Bagshaw described similar findings that oral
cannabinoids provided modest analgesia similar to weak opioids, with dosing limited by adverse
effects such as somnolence, dizziness, blurred vision, and dysphoria.
In 2009, Martín-Sánchez et al. published a meta-analysis of cannabinoids in the treatment
of chronic pain in the Journal Pain Medicine. Their review evaluated 18 RCTs that included a
total of 809 participants. The work by Martín-Sánchez et al. is the first and, to date, only
published meta-analysis of cannabinoid therapy for pain management. While the study makes
reference to “cannabis treatment,” all of the trials included utilized oral cannabinoids (MartínSánchez et al.). This study found cannabinoids reduced visual analogue scales (VAS) of pain by
-0.61 (-0.84 to -0.37) but were offset by adverse effects such as altered perception, impaired
motor function, and altered cognitive function (Martín-Sánchez et al.). Martín-Sánchez et al.
concluded from their analysis that cannabinoids entailed more risk than benefits in the treatment
of chronic pain.
Systematic Reviews of Herbal Cannabis
A systematic review published in 2011 in the British Journal of Clinical Pharmacology
was the first to include analysis of RCTs of inhaled herbal cannabis (Lynch & Campbell). The
review by Lynch and Campbell referenced “cannabinoids” in their study title, but their combined
analysis looked at studies of both oral cannabinoids and inhaled herbal cannabis. They reviewed
a total of 18 RCTs, with four of the trials evaluating inhaled herbal cannabis (Abrams et al.,
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2007a; Ellis et al., 2009; Ware et al., 2010; Wilsey et al., 2008). All four of the inhaled herbal
cannabis trials referenced by Lynch and Campbell are included in this meta-analysis. In their
combined systematic review of both oral synthetic cannabinoids and inhaled herbal cannabis,
Lynch and Campbell concluded that cannabinoids and herbal cannabis are safe and demonstrate
modest effectiveness in the treatment of neuropathic pain as well as fibromyalgia and rheumatoid
arthritis. A particularly significant finding from the Lynch and Campbell review was that all four
of the trials that evaluated herbal cannabis found positive treatment effects without any serious
adverse effects reported. Two of the four herbal cannabis trials evaluated by Lynch and
Campbell found beneficial effects in the treatment of HIV neuropathy, a type of neuropathic pain
that is often not responsive to traditional therapy (Phillips, Cherry, Cox, Marshall, & Rice, 2010).
An article published in 2012 by Grant et al. provided a comprehensive review of both
oral cannabinoids and inhaled herbal cannabis. The review by Grant et al. included evaluation of
several of the first of a series of studies on inhaled herbal cannabis that were conducted with
funding provided by the CMCR. The Medical Marijuana Research Act of 1999 established the
CMCR and provided a total of 8.7 million dollars of funding for research that was conducted
from 2000-2012 (Hecht, 2012; Grant, 2012). The published studies on inhaled herbal cannabis
for pain management conducted with funding from the CMCR, as reviewed by Grant et al.
(2012), demonstrated a consistent reduction in pain intensity of 34-40 percent compared to 17-20
percent with placebo (herbal cannabis with active compounds removed). These findings are
clinically relevant, as a reduction of chronic pain intensity by greater than 30 percent is
associated with improved quality of life (Farrar, Young, LaMoreaux, Werth, & Poole, 2001;
Grant et al., 2012).
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Review of CMCR-Funded Research
The CMCR has provided funding for much of the research relevant to herbal cannabis
that has been published since the turn of the century. Established by a California ballot initiative
in 1999, the CMCR has stated research goals that transition through three stages: research on
smoked cannabis, research on alternative cannabis preparations or delivery systems (such as
vaporization), and research regarding molecules targeting the endocannabinoid system (CMCR,
2010). Clinical trials that have been conducted examining the efficacy of herbal cannabis as an
analgesic agent will be discussed in subsequent chapters. A CMCR-funded RCT that
investigated the pharmacodynamics of herbal cannabis through a model of neuropathic pain with
healthy volunteers was discussed earlier (Wallace et al., 2007). The study by Wallace et al. found
(similar to many pharmaceutical agents) that herbal cannabis likely has a therapeutic window of
dosing. Subtherapeutic dosing of herbal cannabis provides no analgesia, while supratherapeutic
dosing appears to potentially contribute to an increase in pain, or hyperalgesia (Wallace et al.).
An earlier study conducted under similar laboratory conditions that evaluated a model of
analgesia also found a dose-dependent antinociceptive effect (reduced sensation of pain) from
herbal cannabis (Greenwald & Stitzer, 2000). The study by Greenwald and Stitzer also found
that the analgesic effects of cannabis are not affected by opioid antagonists and likely are not
derived from action at opioid receptors. Another CMCR-funded study discussed earlier was the
open trial conducted by Abrams et al. (2011) with chronic pain patients in an inpatient setting.
Abrams et al. (2011) found that vaporized cannabis inhaled three times daily augmented the
effects of opioid therapy without altering plasma opioid levels. Patients in the Abrams et al.
(2011) open trial experienced an average pain reduction of 27% (95% confidence interval 9, 46),

13
a clinically relevant reduction in pain that is consistent with the findings in CMCR-funded RCTs
described by Grant et al. (2012).
Summary
Much of the highest-level evidence (systematic reviews) relevant to cannabis focuses
solely on oral cannabinoid agents. High quality RCTs evaluating the role of herbal cannabis as
an analgesic agent are largely limited to those conducted by the CMCR over the past few years,
with systematic reviews prior to the past few years omitting these results. Results of the reviews
by Lynch & Campbell (2011) and Grant et al. (2012) of inhaled herbal cannabis describe
clinically relevant reductions in chronic pain intensity that is less limited by adverse reactions
than prior reviews that focused solely on oral cannabinoids. While public funding for research
through the CMCR is currently exhausted (Hecht, 2012), there are still additional study results
pending publication. Currently published results on inhaled herbal cannabis suggest a potential
beneficial role in pain management. It is possible that patients may experience less adverse
effects with herbal cannabis than with currently available oral cannabinoids. With continued
research, the CMCR may be able to continue into the latter stage of their stated research
objectives and identify molecular targets in the endocannabinoid system that may balance
clinical efficacy with minimal adverse effects.
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Table 1
States That Have Enacted Medical Marijuana Legislation
State
California
Alaska
Oregon
Washington
Maine
Colorado
Hawaii
Nevada
Montana
Vermont
Rhode Island
New Mexico
Michigan
Arizona
District of Columbia
New Jersey
Delaware
Connecticut
Massachusetts
Illinois
New Hampshire

Year Passed
1996
1998
1998
1998
1999
2000
2000
2000
2004
2004
2006
2007
2008
2010
2010
2010
2011
2012
2012
2013
2013

How Legislation Passed
Ballot (56%)
Ballot (58%)
Ballot (55%)
Ballot (59%)
Ballot (61%)
Ballot (54%)
Senate Bill (32-18 in House; 13-12 in Senate)
Ballot (65%)
Ballot (62%)
Senate Bill (22-7), House Bill (82-59)
Senate Bill (52-10 in House; 33-10 in Senate)
Senate Bill (36-31 in House; 32-3 in Senate)
Ballot (63%)
Ballot (50.1%)
Amendment (13-0 vote)
Senate Bill (48-14 in House; 25-13 in Senate)
Senate Bill (27-14 in House; 17-4 in Senate)
House Bill (96-51 in House; 21-13 in Senate)
Ballot (63%)
House Bill (61-57 in House; 35-21 in Senate)
House Bill (284-66 in House; 18-6 in Senate)

Note. Adapted from “Summary Chart: 20 states and DC that have enacted laws to legalize medical marijuana” by procon.org
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Chapter Three: Methods
This chapter will discuss methods utilized in evaluating and consolidating published data
on herbal cannabis in pain management. Meta-analysis will be conducted on quantitative
findings from published studies. The objective will be to provide organized results regarding the
efficacy of herbal cannabis in pain management that are better powered than those found in
individual studies.
Search Strategy
A literature search of Medline utilizing the keywords “cannabis” or “marijuana” and
“pain” in addition to the title phrases “cannabis” or “marijuana” or “cannabinoid” or
“cannabinoid-opioid” and “pain” or “painful” or “neuropathy” or “antinociceptive” or
“nociceptive” or “analgesic” or “analgesia” or “hyperalgesia” and “trial” or “volunteers” or
“humans” or “interaction” returned nineteen results. Inclusion criteria for study evaluation are
RCTs of inhaled herbal cannabis in the treatment of chronic pain, limited to the English language
studies. No date limitations were set for included studies. Exclusion criteria included any nonrandomized clinical trials. Of the nineteen results, seven of the studies evaluated inhaled herbal
cannabis. Two of the studies evaluated a model of pain in a laboratory setting and were discussed
previously (Greenwald & Stitzer, 2000; Wallace et al., 2007). One study was an open (nonrandomized) trial of opioid interaction with inhaled herbal cannabis (Abrams et al., 2011). Four
of the results met the inclusion criteria of RCTs evaluating inhaled herbal cannabis in chronic
pain patients. An additional article (Corey-Bloom et al., 2012) was retrieved after a manual
search of the list of publications from the CMCR website. After email correspondence with the
primary authors of all retrieved studies, an abstract for an additional article that was in press at
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the time of the initial search was located (Wilsey et al., 2013), bringing the total of studies
meeting inclusion criteria to six (see Appendix). Additional searches utilizing the University of
North Florida library “Onesearch” tool, as well as searches utilizing Pubmed and CINAHL did
not return any additional unique relevant results.
Further review of all study references also did not yield any additional unique relevant
results. A search of the NIH database of registered clinical trials at ClinicalTrials.gov with the
keyword “cannabis” yielded 264 studies, with no additional unique relevant results for
completed studies, either published or unpublished. The last search was completed February 15,
2013. No unpublished studies were located through any source.
Study Selection
Five out of the six studies recruited patients with chronic neuropathic pain (Abrams et al.,
2007a; Ellis et al., 2009; Ware et al., 2010, Wilsey et al., 2008; Wilsey et al., 2013). Two of
these studies were specific to patients with Human Immunodeficiency Virus (HIV) neuropathy
(Abrams et al., 2007a; Ellis et al., 2009). One study evaluated participants with multiple sclerosis
(Corey-Bloom et al., 2012). All of the studies were limited to adult participants. The study by
Abrams et al. (2007a) further limited participants to individuals with self-reported prior
experience with smoked marijuana.
All six studies evaluated were double-blinded, randomized placebo-controlled trials.
Sample sizes ranged from 23 to 50 subjects. One study utilizes a parallel design (Abrams et al.,
2007a), with the other five studies utilizing crossover study designs (Corey-Bloom et al., 2012;
Ellis et al., 2009; Ware et al., 2010, Wilsey et al., 2008; Wilsey et al., 2013). Treatment groups in
all studies received inhaled herbal cannabis with concentrations of THC ranging from 1.29 to 7
percent. Placebos utilized in the studies were herbal cannabis provided by NIDA with active
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compounds removed. Five out of the six studies utilized smoked herbal cannabis for drug
delivery (Abrams et al., 2007a; Corey-Bloom et al., 2012; Ellis et al., 2009; Ware et al., 2010;
Wilsey et al., 2008). One of the six studies utilized vaporized cannabis for drug delivery (Wilsey
et al., 2013). With the exception of the 2010 study by Ware et al., which was conducted in the
province of Quebec in Canada, all studies were conducted in the state of California in the United
States.
Outcome Measures
All six studies evaluated pain intensity as an outcome. Five of the studies evaluated pain
intensity as a primary outcome measure (Abrams et al., 2007a; Ellis et al., 2009; Ware et al.,
2010; Wilsey et al., 2008; Wilsey et al., 2013). One study evaluated muscle spasticity as a
primary outcome and pain intensity as a secondary outcome (Corey-Bloom et al., 2012). Four of
the studies utilized a 100-millimeter visual analogue scale (VAS) as an instrument to measure
pain intensity (Abrams et al., 2007a; Corey-Bloom et al., 2012; Wilsey et al., 2008; Wilsey et al.,
2013). One study utilized an 11-point numeric rating scale (NRS-11) as an instrument to measure
pain intensity (Ware et al., 2010). One study utilized a 20-point verbal rating scale (VRS-20) as
well as a VAS as instruments to measure pain intensity (Ellis et al., 2009). All three of the
instruments utilized to assess pain in the studies have been found to be reliable and valid in the
measurement of pain intensity (Hjermstad et al., 2011). The frequency with which pain intensity
was evaluated varied from study to study. Three of the studies evaluated pain intensity on a daily
basis during the study period (Abrams et al., 2007a; Corey-Bloom et al., 2012; Ware et al.,
2010). One study evaluated pain intensity on a weekly basis during the study period (Ellis et al.,
2009). Two studies (Wilsey et al., 2008; Wilsey et al., 2013) evaluated pain intensity on an
hourly basis for the six hours of each study arm.
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Statistical Analysis
All included studies reported differences between baseline and final pain intensity ratings
for each of the intervention groups. Difference (Cannabis - Placebo) in means of the pain ratings
are reported and tested for significance. Differences in means (Cannabis - Placebo) were
compiled, along with their standard errors, sample sizes, and p values. Meta-analysis was
performed to quantify the effect of treatment (Cannabis) as the standardized mean difference
(SMD) between treatment and control (Placebo) groups in each study as well to achieve an
overall estimate of global effect size based on all studies. Weighting was carried out by reference
to the degree of study precision using the method of the inverse of the variance. The 2013 study
by Wilsey et al. did not report group means or standard errors of means or differences in means
for pain intensity measures. It also used a different method of analysis (Factorial ANOVA)
compared with the other studies. It was not possible to include this study in the meta-analysis
and it was excluded from evaluation. The earlier 2008 study by Wilsey et al. included two
treatment groups in a crossover design, and these were included as separate entries in the metaanalysis.
Heterogeneity between studies was statistically determined using the Q2 test and I2
statistic measures. The results of the Q2 and I2 were insignificant, providing evidence of
homogeneity among the studies evaluated. It is possible to conduct meta-analysis with either
random-effects or fixed effect modeling. Fixed-effect modeling assumes that there is one true
effect size amongst all studies evaluated and that differences in effects are a result of sampling
error (Borenstein, Hedges, Higgins, & Rothstein, 2010). Random-effects modeling allows for the
possibility of different true effect sizes and is appropriate for meta-analysis of studies with
significant variation in populations studied or interventions utilized (Borenstein et al.). After
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ascertaining evidence of homogeneity amongst studies, it was determined that fixed-effect
modeling was appropriate for this meta-analysis. However, meta-analysis was performed with
both fixed-effect and random effects modeling, and both models produced the same results.
Possible publication bias was ascertained by means of funnel plots. Specialized meta-analysis
software, Comprehensive Meta Analysis version 2.2.064, was used to perform the complete
analyses.
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Chapter Four: Results
This chapter will present the quantitative meta-analysis data from five of the six studies
that met the criteria for evaluation. One of the studies (Wilsey et al., 2013) was not included in
the meta-analysis as a result of insufficient reported results that precluded inclusion in the metaanalysis.
Meta-Analysis Results
Results obtained from meta-analysis of efficacy herbal cannabis in reducing chronic pain
intensity are reported in Table 2. The results show that all studies yielded standardized results in
the same direction. The test statistic value of heterogeneity is obtained as 0.990 with a p-value of
0.963 implying between studies heterogeneity was almost certainly absent. This confirms that the
variability between study estimates is too small to assume that they are estimating a different
underlying treatment. The I2 statistic is 0%, which implies that real heterogeneity is 0% to the
total variance across the observed effect estimate.
The test value of overall effect of mean reduction of pain intensity is -4.895 with an
associated p value of 0.003. At the 1% level of significance, this test is statistically significant.
Based on these results, it can be concluded that there is a significant difference between the
Cannabis and Placebo groups in pain intensity reduction. The combined standardized mean
difference (SMD) is -0.362 (Confidence Interval -0.507 to -0.217). The negative SMD value
ensured a greater reduction of pain intensity by Cannabis treatment than the Placebo. The 95%
confidence interval around this estimate is not reasonably wide, indicating no uncertainty in the
pooled result. According to Cohen’s rules, a moderate impact of Cannabis on pain reduction can
be concluded (Cohen, 1988). As a final finding, the funnel plot in Figure 1 shows no sign of
asymmetry. Therefore, there is no evidence of possible publication bias.
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Table 2
Meta-Analysis of Herbal Cannabis in Reduction of Pain Intensity
Statistics for each study
Study name

Std. diff. in

Standard

means

error

Corey-Bloom et al., 2012

-0.467

0.192

Ware et al., 2010

-0.441

Ellis et al., 2009

Lower

Upper

limit

limit

0.037

-0.844

0.218

0.048

-0.427

0.197

Wilsey et al., 2008 (3.5%)

-0.345

Wilsey et al., 2008 (7%)

Variance

Standardized Mean Difference, Fixed Effects, 95% C.I.
Z-value

p-value

-0.090

-2.429

0.015

-0.869

-0.013

-2.019

0.043

0.039

-0.814

-0.040

-2.165

0.030

0.182

0.033

-0.702

0.012

-1.897

0.058

-0.320

0.181

0.033

-0.675

0.035

-1.765

0.077

Abrams et al., 2007

-0.272

0.144

0.021

-0.555

0.010

-1.891

0.059

Combined

-0.362

0.074

0.005

-0.507

-0.217

-4.895

0.000

Test for Heterogeneity: Q = 0.990, p-value = 0.963, I2 = 0.00%
Test for overall effect: Z = -4.895, p-value = 0.000
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Chapter Five: Discussion
The following chapter will discuss the results from the meta-analysis. Implications for
practice will be discussed, as well as the limitations of this study and implications for future
research.
Results of this meta-analysis demonstrate a statistically significant reduction in pain
intensity in chronic pain patients receiving inhaled herbal cannabis. These findings are consistent
with the findings discussed in a recent narrative review (Grant et al., 2012). The narrative review
by Grant et al. included discussion of four (Abrams et al., 2007a; Ellis et al., 2009; Ware et al.,
2010; Wilsey et al., 2008) of the six studies that met inclusion criteria, with the two most recent
studies (Corey et al., 2012; Wilsey et al., 2013) not included in the discussion. The findings in
the combined synthetic cannabinoid and herbal cannabis review by Lynch and Campbell (2011)
were similar to the herbal cannabis discussion in the Grant et al. review, with the combined
review describing modest reductions in pain and the herbal cannabis review describing
significant reductions in pain intensity, both consistent with the findings in this meta-analysis.
Additionally, results of this meta-analysis are consistent with the sole RCT that was excluded
from data analysis (Wilsey et al., 2013). Compiled data from all available RCTs utilizing RCTs
demonstrate moderate but statistically significant efficacy in reducing pain intensity in chronic
pain patients. The data also lacked evidence of publication bias.
Implications for Practice
In states where regulations permit medical usage, herbal cannabis may represent an
option for chronic pain patients as an analgesic adjuvant with opioid-sparing properties (Abrams
et al., 2011). These findings present a number of implications for advanced nursing practice.
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However, the direct relevance of these findings varies significantly between different practice
settings.
Within the perioperative setting, the future therapeutic potential of the substance is
essentially completely negated by practical limitations to administration as well as some
potential concerns for pharmaceutical interactions and airway complications. For example,
chronic cannabis usage has been shown to increase propofol dosage requirements for laryngeal
mask airway placement (Flisberg et al., 2009). Although extremely rare, one case study
documented an instance of acute uvulitis and partial airway obstruction that was thought to have
resulted from recently smoked cannabis (Mallat, Roberson, & Brock-Utne, 1996). The authors of
this single case study suggested that the higher combustion temperature of cannabis (relative to
tobacco) paired with deeper and sustained inhalation might account for increased mucous
membrane irritation in some cannabis smokers (Mallat et al.). Because of these concerns,
recommendations in some anesthesia literature are that elective surgical procedures should be
delayed for patients that have smoked herbal cannabis within 72 hours prior to surgery
(Dickerson, 1980; Mallat et al., 1996). Other recommendations from anesthesia literature include
simply treating patients with a history of smoking cannabis similarly to patients with a history of
smoking tobacco due to potential similarities in airway hyperreactivity (Bryson & Frost, 2011).
Existing research demonstrates efficacy of herbal cannabis as an analgesic agent.
However, a significant amount of additional research is needed to achieve the complete goals of
the CMCR of establishing efficacy with inhaled cannabis prior to researching other delivery
methods and eventually researching molecules that target the endocannabinoid system (Grant,
2012). It is possible that targeted delivery of cannabinoid agonists may eventually be feasible
within the perioperative setting for acute pain management. However, current delivery methods
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create a potential for adverse airway reactions that, in addition to potential drug interactions,
make herbal cannabis unsuitable for the perioperative period.
Within the outpatient and primary care settings, patients may present who are using
cannabis or (in jurisdictions where this is permitted) are seeking information and
recommendations regarding the substance from practitioners. While further research is still
needed to establish optimum dose and frequency, the findings of this meta-analysis support the
recommendation of herbal cannabis as an adjunct analgesic agent for chronic pain patients.
In the palliative care setting, herbal cannabis provides the additional benefits of
antiemetic properties and appetite stimulation (Machado Rocha et al., 2008; Tramér et al., 2001).
Since the substance remains prohibited under federal law, providers do not “prescribe” herbal
cannabis per se, but rather “recommend” it to patients, subject to state regulations that vary
considerably. With the rapid pace of regulatory changes in this area, providers working in
jurisdictions where medical cannabis initiatives are proposed or have passed may encounter
questions from patients regarding the efficacy of the substance. The findings of this metaanalysis support the efficacy of herbal cannabis in reducing pain intensity in patients suffering
from chronic pain.
Study Limitations
This meta-analysis had several limitations related to the available literature on this topic.
There are a very limited number of RCTs from which to consolidate data. The RCTs that are
available have small numbers of participants and vary somewhat in specific patient population
and dosing regimen. As shown in the appendix, the RCTs included in this meta-analysis utilized
herbal cannabis with concentrations of active compounds that varied somewhat from study to
study. Additionally, the frequency of dosing and delivery method was not consistent across
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studies. This meta-analysis was limited to English-language publications and did not evaluate
any unpublished studies.
Some of these limitations are inherent to the technique of meta-analysis itself. A unique
issue with studies utilizing herbal cannabis is the regulatory difficulty conducting such studies.
Studies utilize herbal cannabis supplied by NIDA with uniform concentrations of active
compounds (Grant, 2012). Research utilizing herbal cannabis has additional bureaucratic
difficulties that may limit studies from being repeated to better confirm findings. Rather, what
are available within the limited research that has been conducted are studies that evaluate the
efficacy of herbal cannabis in slightly different and unique ways with slightly different
participant populations.
Implications for Future Research
Trials utilizing herbal cannabis are very limited and involve considerable regulatory
restrictions to conduct. There is a great deal that is not well understood regarding the therapeutic
value of the substance. In regards to the efficacy of herbal cannabis in treating chronic pain, there
is a need for clinical trials to determine optimum dosage, timing, and delivery methods.
Additionally, larger studies that stratify specific chronic pain populations could be conducted to
determine which patients might be most responsive to herbal cannabis therapy.
The sole RCT of herbal cannabis for chronic pain that was excluded from meta-analysis
(Wilsey et al., 2013) did demonstrate similar findings of moderate analgesia in patients with
treatment-resistant neuropathic pain. One unique aspect to the 2013 study by Wilsey et al. is that
it is the first RCT to utilize vaporization as a delivery method for the inhaled cannabis. A prior
open trial by Abrams et al. in 2011 used vaporized herbal cannabis and also found reduced pain
intensity as well as reduced opioid consumption in chronic pain patients. Vaporization is able to
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deliver similar levels of active compounds with patients experiencing lower plasma carbon
monoxide levels and a general patient preference for vaporization over smoking (Abrams et al.,
2007b). With the known pulmonary complications of smoked cannabis (Bryson & Frost, 2011),
there is a need for further studies using the safer delivery method of vaporized cannabis to better
establish analgesic efficacy of vaporized cannabis in chronic pain patients. Another possibility
for future research might include a comparison of efficacy between different delivery methods
such as smoked, vaporized, and ingested herbal cannabis. It is possible that first-pass metabolism
may play a role in the lower efficacy seen with oral cannabinoids. However, research in this area
relates primarily to oral ingestion of specific cannabinoid extracts rather than unaltered herbal
cannabis. Further research might reveal the impact of other active compounds in herbal cannabis
as well as the impact of first-pass metabolism that may possibly limit the efficacy of oral
delivery of herbal cannabis for some uses.
Conclusion
Medicinal use of herbal cannabis is a controversial subject, but one that is in need of
more evidence through objective, quality research trials. In light of the evolving attitudes
regarding marijuana, it is an opportune time to investigate this substance further. More than half
of Americans are now in favor of marijuana legalization, a statistic that is in stark contrast to
attitudes towards the substance in prior decades (Pew Research Center, 2013). In the current
sociopolitical environment, research can be conducted without as much concern for research
findings disrupting the status quo.
The findings of this meta-analysis are consistent with all prior research on the subject,
further demonstrating a moderate reduction in pain intensity with minimal side effects in chronic
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pain patients with the use of herbal cannabis. Additional research is needed to better establish
optimum therapeutic dosing regimens and factors related to safety and adverse reactions.
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Appendix: Experimental Studies Investigating Herbal Cannabis and Chronic Pain
Author
(Date)
Wilsey et
al. (2013,
in press)

Design

Sample

Outcome

Intervention

RCT
(crossover)

39 participants

VAS

Vaporized
cannabis (or
placebo
cannabis)

CoreyBloom et
al. (2012)

RCT
(crossover)

37 participants

VAS

Ware et
al.
(2010)

RCT
(crossover)

23 participants

VAS

Ellis et
al.
(2009)

RCT
(crossover)

28 participants

Descriptor
Differential
Scale
(DDS) &
VAS

Wilsey et
al.
(2008)

RCT
(crossover)

38 participants

VAS

Smoked
cannabis (or
placebo
cannabis) daily
x3 days, 11 day
washout
between
treatment groups
Random
assignment to
receive smoked
cannabis three
times a day at
four potencies
(0%, 2.5%, 6%,
9.4%
tetrahydrocanna
binol) over four
14-day periods
in a crossover
trial.
Random,
double-blind
assignment to
smoke herbal
cannabis with
8%
tetrahydrocanna
binol or 1%
(placebo) herbal
cannabis four
times daily for
five consecutive
days in
crossover trial
with two-week
washout period .
Random
assignment to
either high-dose
(7%
tetrahydrocanna

Results

Limitations

Analgesic effects
observed in both
“high-dose” and
“low-dose”
groups. 30%
reduction in pain
intensity
compared to
placebo.
VAS decreased by
5.28 points more
than placebo
(p=0.008)

Potential for
unmasking of
blinding in
crossover design

Single inhalation
of 9.4%
tetrahydrocannabi
nol herbal
cannabis three
times daily for
five days reduced
pain intensity and
improved sleep. In
0% vs. 9.4%
groups, pain was
5.4 vs. 6.1 (95%
CI, 0.02-1.4).
Pain relief was
greater in active
cannabis group vs.
placebo (-3.3
points on DDS,
effect size = 0.60;
p= 0.016).
Subjects
achieving ≥30%
pain reduction
with active
cannabis vs.
placebo were 0.46
(95% CI 0.28,
0.65) and 0.18
(0.03, 0.32).
Analgesic effects
were observed in
both “high-dose”
and “low-dose”
groups when

Small number of
participants.
Tetrahydrocannabi
nol concentration
limited by legal
availability. The
use of smaller
fixed dosing of
herbal cannabis
may have limited
the effect size.

Some participants
prior cannabis
users (selfselection bias,
potential
unblinding)

Potential placebo
effects, as most
subjects were able
to differentiate
between treatment
and placebo
groupings by the
end of second
crossover period.

Brief observational
period (6 hour
sessions), possible
placebo effect.
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Abrams
et al.
(2007a)

RCT

50 participants

VAS

binol), low-dose
(3.5%
tetrahydrocanna
binol), or
placebo
cannabis.
Patients inhaled
smoked herbal
cannabis during
3 separate 6
hour sessions,
receiving each
treatment group
once, in random
order.
Random
assignment to
3.56% cannabis
cigarettes or
placebo
(cannabinoids
extracted)
group, with
cigarettes
smoked three
times a day for
five days.

compared with
placebo (VAS
difference per
minute of -0.0035,
95% CI [-0.0063,
-0.0007])

Cannabis
significantly
reduced pain vs.
placebo.
Daily pain was
reduced by
median of 34%
(IQR = -71, -16)
vs. median of
17% (IQR = -29,
8) for placebo.

Single
tetrahydrocannabin
ol concentration
may limit
comparison of
findings with other
studies.
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